肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.
Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
近年来免疫疗法研究重点关注嵌合抗原受体修饰 T 细胞（CAR-T）。CAR-T 疗法已用于临床治疗血液系统恶性肿瘤，并取得满意疗效；但将 CAR-T 免疫疗法应用于实体瘤仍具有挑战。尽管如此，针对前列腺癌（PCa）的 CAR-T 免疫疗法已显示一定前景，为晚期转移性 PCa 患者带来希望。本综述旨在阐述不同前列腺肿瘤相关抗原靶点，如前列腺特异性膜抗原和前列腺干细胞抗原，以及这些靶点的作用；同时讨论相应靶点在临床研究中的应用现状。为提高 CAR-T 免疫疗法疗效，文章探讨多模态免疫疗法、化疗与 CAR-T 联合治疗的潜在应用，并简要阐述实体瘤带来的障碍。未来研究应致力于发现新的潜在靶点，并建立新的模型，以克服肿瘤异质性和肿瘤微环境免疫抑制等实体瘤固有障碍。
Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells (CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic malignancies with satisfactory effectiveness.
However, the application of CAR-T immunotherapy in solid tumors remains challenging. Even so, current CAR-T immunotherapies for prostate cancer (PCa) have shown some promise, giving hope to patients with advanced metastatic PCa. This review aimed to elucidate different types of prostate tumor-associated antigen targets, such as prostate-specific membrane antigen and prostate stem cell antigen, and their effects.
The current status of the corresponding targets in clinical research through their applications was also discussed. To improve the efficacy of CAR-T immunotherapy, we addressed the possible applications of multimodal immunotherapy, chemotherapy, and CAR-T combined therapies. The obstacles of solid tumors were concisely elaborated.
Further studies should aim to discover novel potential targets and establish new models by overcoming the inherent barriers of solid tumors, such as tumor heterogeneity and the immunosuppressive nature of the tumor microenvironment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
